|1.70||-0.0400||-2.30%||Vol 26.45M||1Y Perf -72.34%|
|Jun 24th, 2022 16:00 DELAYED|
|- -||0.01 0.59%|
|Target Price||3.00||Analyst Rating||Hold 3.33|
|Potential %||76.47||Finscreener Ranking||★★+ 47.17|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 67.72|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||18.44||Earnings Rating||Strong Buy|
|Market Cap||244.59M||Earnings Date||3rd Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||3rd Aug 2022|
|Estimated EPS Next Report||-0.41|
|EPS Growth Next 5 Years %||40.20|
|Avg. Weekly Volume||44.39M|
|Avg. Monthly Volume||15.57M|
|Avg. Quarterly Volume||15.34M|
Clovis Oncology Inc. (NASDAQ: CLVS) stock closed at 1.7 per share at the end of the most recent trading day (a -2.3% change compared to the prior day closing price) with a volume of 26.45M shares and market capitalization of 244.59M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Clovis Oncology Inc. CEO is Patrick J. Mahaffy.
The one-year performance of Clovis Oncology Inc. stock is -72.34%, while year-to-date (YTD) performance is -37.27%. CLVS stock has a five-year performance of -98.21%. Its 52-week range is between 0.581 and 6.65, which gives CLVS stock a 52-week price range ratio of 18.44%
Clovis Oncology Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 7.70, a price-to-sale (PS) ratio of 0.69, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -53.29%, a ROC of -18.45% and a ROE of 100.94%. The company’s profit margin is -%, its EBITDA margin is -150.30%, and its revenue ttm is $144.95 Million , which makes it $1.01 revenue per share.
Of the last four earnings reports from Clovis Oncology Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Clovis Oncology Inc.’s next earnings report date is 03rd Aug 2022.
The consensus rating of Wall Street analysts for Clovis Oncology Inc. is Hold (3.33), with a target price of $3, which is +76.47% compared to the current price. The earnings rating for Clovis Oncology Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Clovis Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Clovis Oncology Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.72, ATR14 : 0.26, CCI20 : 173.42, Chaikin Money Flow : -0.24, MACD : 0.13, Money Flow Index : 84.87, ROC : 133.93, RSI : 69.48, STOCH (14,3) : 61.52, STOCH RSI : 0.88, UO : 49.71, Williams %R : -38.48), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Clovis Oncology Inc. in the last 12-months were: Daniel W. Muehl (Option Excercise at a value of $0), Daniel W. Muehl (Sold 25 468 shares of value $62 465 ), Gillian C. Ivers-Read (Option Excercise at a value of $0), Gillian C. Ivers-Read (Sold 25 259 shares of value $56 800 ), Lindsey Rolfe (Option Excercise at a value of $0), Lindsey Rolfe (Sold 24 253 shares of value $59 471 ), Paul Edward Gross (Option Excercise at a value of $0), Paul Edward Gross (Sold 27 871 shares of value $64 008 ), Thomas C. Harding (Option Excercise at a value of $0), Thomas C. Harding (Sold 13 654 shares of value $31 535 )
Tue, 14 Jun 2022 14:05 GMT Analysts Conflicted on These Healthcare Names: Clovis Oncology (CLVS) and OrthoPediatrics (KIDS)- TipRanks. All rights reserved.
Mon, 06 Jun 2022 15:55 GMT Clovis Oncology (CLVS) Gets a Hold Rating from H.C. Wainwright- TipRanks. All rights reserved.
Fri, 01 Apr 2022 12:04 GMT Clovis Jumps 22.4% on Positive Data for Rubraca- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.